Antiviral Library Entry

ISO 17025–ACCREDITED LABORATORY ENVIRONMENT

Antiviral Drugs DMPK and Bioanalytical Services

Creative Proteomics provides DMPK, bioanalytical, metabolite profiling, intracellular exposure, and biomarker-related support for antiviral drug research. This section of our drug library helps researchers explore analytical strategies for major antiviral groups, including herpesvirus antivirals, influenza antivirals, HIV antivirals, hepatitis antivirals, and related antiviral agents.

Unlike antibacterial workflows that often emphasize extracellular parent-drug exposure, antiviral research frequently depends on activation, intracellular retention, viral replication context, combination-regimen exposure, and host immune-response readouts. Studies may require parent drugs, prodrug intermediates, active metabolites, phosphorylated intracellular forms, viral-load-associated markers, or cytokine-linked interpretation.

Explore Antiviral Classes Explore Related Services

Active FormsParent drugs, prodrug intermediates, and intracellular metabolites.

Viral MechanismsPolymerase, protease, integrase, neuraminidase, and replication readouts.

Combination ContextMulti-antiviral panels, boosters, DDI behavior, and transporter effects.

Antiviral Study Logic Activation → Exposure → Response

🦠

Viral Research AreaHerpesvirus, influenza, HIV, hepatitis, and related antiviral compound classes

⚙

Activation & TransformationProdrug conversion, active metabolites, phosphorylated forms, oxidative or conjugated products

🔬

Intracellular / Tissue ExposureCell lysates, intracellular extracts, plasma, tissue, liver-associated, or respiratory-relevant matrices

📊

Viral & Host ResponseViral load, replication markers, IFN signals, cytokines, immune activation, and combination exposure

Antiviral Library

Explore Antiviral Drug Classes

HSV

Herpesvirus Antivirals

Nucleoside analog and prodrug studies may need to connect parent-drug exposure with active forms, renal handling, and viral DNA replication context.

Parent-drug quantification
Prodrug conversion
Active metabolite support
Intracellular exposure

Explore →

Flu

Influenza Antivirals

Influenza antiviral workflows often emphasize early exposure windows, parent-active metabolite relationships, respiratory-relevant matrices, and viral response.

Active metabolite quantification
Early time-course exposure
Respiratory matrix support
Viral-response readouts

Explore →

HIV

HIV Antivirals

HIV antiviral research often requires multi-drug panels, intracellular active metabolite analysis, CYP-related metabolism, boosters, and DDI-focused bioanalysis.

Combination panels
Intracellular active forms
CYP / DDI support
Transporter-related exposure

Explore →

HBV

Hepatitis Antivirals

Hepatitis antiviral studies may connect systemic exposure with liver-associated activity, active metabolites, transporter behavior, and viral replication readouts.

Liver-related exposure
Active metabolite profiling
Transporter context
Viral replication readouts

Explore →

Research Questions in Antiviral Studies

Where Is the Active Form, and How Should Response Be Read?

Antiviral projects often begin with a question about where the active form is generated, where the drug needs to act, and how exposure should be connected to viral or host-response readouts. The analytical route changes when a compound acts as a parent drug, requires intracellular activation, undergoes prodrug conversion, belongs to a combination regimen, or must be interpreted alongside viral replication markers.

Is the measured analyte active?Should the method quantify the parent antiviral, an active metabolite, a phosphorylated intracellular form, or a prodrug-derived product?

Is intracellular exposure central?Do cell lysates, intracellular extracts, or phosphorylated metabolite measurements better represent antiviral activity than plasma parent-drug levels?

Is prodrug conversion involved?Should the workflow separate the administered compound, conversion intermediates, active form, and inactive transformation products?

Is this a combination regimen?Does the study require simultaneous quantification of multiple antivirals, boosters, or parent–metabolite pairs?

Are DDI or transporter effects relevant?Could CYP metabolism, transporter-associated disposition, or pharmacokinetic boosting alter antiviral exposure?

Which response markers matter?Should exposure be paired with viral load, replication markers, IFN signals, cytokines, immune activation, or cell-population readouts?

Exposure • Activation • Viral Response

Connecting Antiviral Exposure with Viral Mechanism and Host Response

Antiviral bioanalysis is most useful when concentration data are interpreted in relation to viral life-cycle biology. A parent-drug PK curve may show systemic exposure, but antiviral studies often need to determine whether the active form is generated, retained intracellularly, altered by combination treatment, and aligned with viral or immune-response shifts.

Systemic exposureMeasure parent antiviral concentration in plasma, serum, tissue, or regimen-specific sample sets.

→

Activation routeEvaluate prodrug conversion, active metabolites, phosphorylated forms, or intracellular retention.

Mechanism layerPolymerase inhibition, reverse transcriptase inhibition, protease inhibition, integrase inhibition, or neuraminidase inhibition.

→

Response contextViral load, replication markers, IFN-α, IFN-γ, cytokines, immune activation, or cell-population readouts.

Regimen complexityCombination antivirals, boosters, CYP behavior, transporter involvement, or DDI-related concentration shifts.

→

Study outputActivation-aware exposure interpretation and method-ready data for antiviral research workflows.

Antiviral Research Focus and Potential Readouts

Antiviral Research Focus	Potential Analytical or Response Readouts
Nucleoside / nucleotide analog activation	Parent drug, phosphorylated active metabolites, intracellular exposure
Prodrug conversion	Parent compound, conversion intermediates, active metabolite, conversion efficiency
Viral polymerase inhibition	Active metabolite level, viral replication-related readouts, parent–metabolite relationship
Protease or integrase inhibitor studies	Parent-drug exposure, CYP-related metabolites, DDI-related concentration profiles, regimen context
Liver-associated antiviral activity	Plasma and liver-associated exposure, parent–metabolite ratio, transporter-related context
Viral-response interpretation	Viral load, IFN-α, IFN-γ, cytokine panels, immune activation markers
Combination antiviral studies	Multi-drug quantification, parent–metabolite panels, interaction-related exposure profiles

Bioanalytical and DMPK Service Options

Service Modules for Antiviral Studies

Creative Proteomics supports antiviral research through targeted, activation-aware, and mechanism-linked analytical workflows. Service modules can be selected around parent-drug exposure, intracellular active forms, prodrug conversion, metabolite profiling, DDI behavior, combination regimens, or viral-response interpretation.

Antiviral Parent Drug Quantification

Quantify antiviral parent compounds when systemic concentration, tissue exposure, or combination-regimen exposure must be measured across time points.

Parent antiviral concentration measurement
Plasma, serum, urine, tissue, or cell-associated samples
Time-course sample analysis
Exposure profiling
Parent-drug analysis for combination studies

Active Metabolite and Intracellular Analyte Analysis

Measure active metabolites, phosphorylated forms, and cell-associated analytes that may not be represented by plasma parent-drug levels alone.

Active metabolite quantification
Phosphorylated metabolite analysis
Intracellular exposure assessment
Cell lysate or intracellular extract analysis
Low-abundance analyte method development

Prodrug Conversion and Metabolite Profiling

Clarify activation routes, clearance pathways, and relationships between administered compounds, intermediates, and active forms.

Prodrug conversion product analysis
Phase I / II metabolite support
Active metabolite confirmation
Suspected metabolite screening
LC-MS/MS or HRMS-based profiling

DDI, Transporter, and Combination Panel Support

Evaluate multi-drug exposure, parent–metabolite pairs, CYP-related metabolism, transporter disposition, and regimen-specific exposure changes.

CYP-related metabolism support
DDI-related bioanalysis
Transporter-associated exposure support
Multi-antiviral LC-MS/MS panels
Comparative exposure profiling

Related Services

Relevant Services for Antiviral-Related Projects

These service modules can be applied individually or combined into a customized workflow based on target antiviral, activation route, sample type, intracellular activity, regimen complexity, concentration range, and study objective.

Ready to Quantify Your Lead Compound or Metabolite?

Share your matrix type, sample count, and expected range—feasibility routing will confirm whether direct quantification is fit-for-purpose or method development is recommended.

Want to browse compounds, matrices, and assay coverage? Explore the Library →